Indian Government Denies Patent Application For Copaxone; Natco Pharma Says Obstacles Removed For Supply Of Generic Version Worldwide
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a decision that could trigger a bigger battle, the Indian Patent Office has denied a patent application filed by an Israeli company for Copaxone(glatiramer), an innovative drug used in the treatment of multiple sclerosis
You may also be interested in...
Teva Appeals In Delhi High Court To Block Natco’s Export Of Glatiramer
Teva’s petition to stop Natco from exporting glatiramer was dismissed by the Delhi High in February. The company has now appealed to a double bench in its continued efforts to prove that Natco’s move to export the compound infringes its international patents.
Teva Appeals In Delhi High Court To Block Natco’s Export Of Glatiramer
Teva’s petition to stop Natco from exporting glatiramer was dismissed by the Delhi High in February. The company has now appealed to a double bench in its continued efforts to prove that Natco’s move to export the compound infringes its international patents.
Indian Court Dismisses Teva’s Plea To Halt Natco’s Generic Copaxone Exports
A two-year patent infringement case reached a conclusion with the Delhi High Court favoring Natco in a dispute over generic versions of Teva’s top-selling MS drug. If the court had sided with Teva, launch plans for the United States may have been delayed for Natco’s partner Mylan.